On rotary tablet presses used for veterinary oral solid dosage forms, the hydration state of dibasic calcium phosphate directly influences whether direct compression runs remain within the required weight and hardness window. The dihydrate powder with a volume median diameter between 75 µm and 150 µm and a tapped density of 0.90–1.00 g/cm³ is selected for direct compression because the crystalline water contributes to compactability and tablet hardness, but the same water becomes a process liability when press dwell time exceeds 35 ms and compact temperature rises. In medicated tablets where the substance functions as a filler-diluent and mineral source, the formulation addition range is 20–45% w/w; in targeted calcium and phosphorus supplement tablets, the addition ratio is raised to 55–75% w/w, at which point the mineral phase governs tensile strength and friability rather than the binder concentration. Compliance is anchored to the current USP-NF monograph for Dibasic Calcium Phosphate Dihydrate and to 21 CFR 210/211 for finished veterinary drug manufacturing, including in-process sampling and testing under 21 CFR 211.110. Batch release includes USP <905> uniformity of dosage units, USP <701> disintegration, and USP <1174> powder flow characterization; where the powder enters the feed frame with an angle of repose greater than 35°, colloidal silicon dioxide is added at 0.5–1.0% w/w to restore consistent die fill.

Direct compression on a rotary press is performed at precompression force 3–5 kN and main compression force 12–22 kN, with punch speed adjusted to keep dwell time below 35 ms. Failure modes observed on production-scale equipment include cap formation when main compression exceeds 25 kN for dihydrate-containing blends, and sticking when the feed hopper is exposed to ambient relative humidity above 60% for more than 2 hours. Where the API is roller-compacted before compression, the resulting granulate is milled through a 0.8 mm screen and blended with a lubricant such as magnesium stearate at 0.5–1.0% w/w. Terminal product types include film-coated tablets for companion animals, uncoated chewable tablets, and scored tablets for divided oral dosing. Pre-drying of the granulated blend is mandatory when residual moisture exceeds 3.0%; anhydrous dibasic calcium phosphate in high-humidity packaging areas requires desiccant-lined closures to prevent moisture uptake, powder agglomeration, and feed-frame bridging.

Batch-to-batch variation in tapped bulk density is the primary source of fill-weight drift when dibasic calcium phosphate is run through tamping-pin capsule filling equipment. The anhydrous grade with a tapped density of 1.10–1.30 g/cm³ and a Hausner ratio below 1.25 is preferred for two-piece hard gelatin or hydroxypropyl methylcellulose capsules because it permits tamping pin compression to form stable plugs without excessive piston wear. In capsule formulations the addition level is 25–50% w/w as a diluent-filler in medicated capsules; for pure mineral supplement capsules intended for equine or bovine oral administration, the content can reach 65–75% w/w, with the remaining mass composed of a lubricant such as magnesium stearate at 0.5–1.0% w/w and a disintegrant such as croscarmellose sodium at 2–4% w/w. Compliance is established under USP <905> for weight variation, USP <701> for disintegration, and USP <232>/<233> for elemental impurities; if the capsule is part of a registered veterinary drug product, finished dosage form release follows 21 CFR 211.165.

On a tamping-pin machine with 5 tamping stations, capsule size 00 can be filled to a target weight of 700–900 mg for equine dose units, but the number of tamping pin compression cycles must be limited to 3–5 because additional cycles densify the powder and delay disintegration beyond the 30 min compendial limit. Production-line failure data indicate that capsule bodies with a powder bed depth variability greater than 3 mm lead to weight RSD above 2.0%; pre-milling through a 30-mesh screen and controlling hopper humidity below 50% reduce this variation. Terminal products include veterinary hard capsules for oral mineral supplementation, prescription capsules containing antiparasitic actives in a dibasic calcium phosphate diluent matrix, and HPMC capsules for companion animals where gelatin is not permitted.

What Limits Syringeability and Sedimentation in Aqueous Veterinary Drench Formulations?

Because dibasic calcium phosphate is practically insoluble in aqueous media across the pH range 3.0–7.5, the term “solution” in veterinary oral drench development is replaced by “suspension” when this API is used. The formulation addition ratio is 10–25% w/v in oral drench formulations intended for cattle and sheep mineral supplementation; above 25% w/v, the yield stress increases beyond the range suitable for dosing-syringe extrusion and oral administration through a 16G nozzle. Suspension stability is controlled by reducing particle size to a D90 of ≤25 µm using a colloid mill operated at a rotor gap of 50–100 µm, followed by addition of xanthan gum at 0.15–0.35% w/v and citrate buffering to maintain pH 5.5–7.5. The finished suspension viscosity at 25 °C is set between 300 mPa·s and 800 mPa·s, measured on a rotational viscometer at 20 rpm, because below 300 mPa·s sedimentation occurs within 4 hours, while above 800 mPa·s the product no longer passes through a 16G oral dosing syringe. Compliance for preserved multi-dose drench packs is anchored to USP <51> for antimicrobial effectiveness, USP <698> for deliverable volume, and 21 CFR 211 when the product is registered as a veterinary drug; where the formulation is marketed as a feed supplement drench, Regulation (EU) 2019/6 and national residue regulations govern the label.

Production-scale mixing is carried out with a high-shear disperser followed by recirculation through a colloid mill until the mean particle size stabilizes; batches that bypass colloid milling show a particle-size tail above 75 µm and settle into a non-redispersible sediment within 6–8 hours. Terminal product types include oral drench suspensions, paste formulations for equine oral administration, and liquid mineral supplements for mixing into drinking water. Injectable mineral use is not a primary downstream application for this insoluble salt; published formulation data for injectable veterinary calcium phosphate dibasic suspensions remains limited, and any parenteral claim would require a separate aseptic process, endotoxin control under USP <85>, and tissue-irritation studies before registration.

Calcium and Phosphorus Carrier Function in Type B Medicated Premix Blending

In Type B medicated premix blending lines, the high true density of anhydrous dibasic calcium phosphate relative to corn cob or rice hull carriers creates a segregation profile that becomes measurable when the blender is discharged through a pneumatic conveyor. As a macro-mineral phosphorus source in complete feed, dibasic calcium phosphate is included at 0.5–2.0% w/w of the final ration dry matter, while in the premix itself the substance is used as a high-density carrier-diluent at 30–60% w/w to provide calcium and phosphorus potency in a concentrated Type B mixture. The production process uses a horizontal ribbon blender with a working volume of 2–3 m³, fill level 60–70%, mixing time 4–6 minutes, and ribbon tip speed of 1.5–2.5 m/s; after mixing, the coefficient of variation for an added tracer should remain below 5%. Regulatory compliance is governed by 21 CFR Part 225 for medicated feed manufacturing, Regulation (EC) 1831/2003 for feed additives, Directive 2002/32/EC for undesirable substances, and the AAFCO Official Publication for mineral feed ingredient definitions. Fluorine content is monitored against the Directive 2002/32/EC maximum for phosphate feed materials, and acid-insoluble residue is tested to control non-phosphate mineral contamination.

Segregation failure on production lines is observed when the particle-size difference between dibasic calcium phosphate and the other premix fractions exceeds 100 µm and the blend is conveyed over distances greater than 10 m at air velocities above 20 m/s. Terminal product types include Type B medicated feed premixes for swine and poultry, free-choice cattle mineral mixes diluted with salt and molasses, and custom vitamin-mineral premixes for feed mills. Published data for specific pneumatic transfer configurations is limited, but the segregation mechanism is consistent with established powder technology: fine phosphate particles migrate to the bin periphery while larger organic carriers remain in the center, an effect reduced by post-transfer remixing or by granulating the premix to a uniform 0.5–1.0 mm particle size.

Determining Wet Granulation Endpoint Through Torque and Moisture Analysis

Wet-mass torque readings from a high-shear granulator provide a repeatable endpoint when dibasic calcium phosphate constitutes 40–70% w/w of the granule formulation. The process begins with dry blending of the API with a binder such as povidone K30 at 3–5% w/w and, where required, a disintegrant such as sodium starch glycolate at 2–4% w/w; purified water is added at 25–35% w/w relative to dry mass over 3–4 minutes. In a 300 L high-shear granulator, impeller speed is set at 150–200 rpm and chopper speed at 1,500–3,000 rpm; the endpoint is reached when impeller power draw rises from the dry-mix baseline by 15–25% and the wet mass forms a hand-pressable agglomerate with a moisture content of 12–18%. Wet mass is transferred to a fluid-bed dryer operated at inlet temperature 65–70 °C and product temperature 40–45 °C; drying is stopped at residual moisture 2.0–3.5% and the dried granules are milled through a 0.710 mm screen. Compliance is anchored to USP <731> for loss on drying, Ph. Eur. 2.9.12 for sieve analysis, VICH GL18 for residual solvents, and USP <232>/<233> for elemental impurities.

Overgranulation occurs when wet massing time exceeds 5 minutes at high chopper speed, producing dense granules with low intragranular porosity and prolonged disintegration beyond 15 minutes in compendial media. Dihydrate-containing granules must not be exposed to product temperatures above 60 °C for more than 30 minutes because lattice water loss alters the crystalline surface and increases friability; formulations requiring higher drying temperatures are switched to the anhydrous grade. Terminal products include sachet granules for oral suspension reconstitution, granular mineral supplements for top-dressing on feed, and paste-forming granules that are combined with glycerol and polyethylene glycol in equine oral syringes. The low solubility of the mineral reduces the risk of burst release, but it also means that dissolution testing, where applicable, measures disintegration and suspension formation rather than molecular dissolution of the phosphate phase.

When Fluid-Bed Agglomeration Replaces Dry Blending for Oral Powder Reconstitution

When a low-dust water-dispersible oral powder is required for administration through drinking water or milk replacer, dry blending of dibasic calcium phosphate produces unacceptable segregation and dusting, so fluid-bed agglomeration is used. The API is loaded at 35–65% w/w into a top-spray fluid-bed granulator, and an aqueous binder solution containing 5–10% w/w maltodextrin or povidone is sprayed at 180–250 g/min through a 1.2 mm two-fluid nozzle. Inlet air temperature is held at 60–75 °C, product temperature is kept below 45 °C, and atomization air pressure is set at 1.5–2.5 bar; these conditions produce low-density agglomerates with a Hausner ratio below 1.20 and a mass median diameter of 250–500 µm. Final moisture is controlled at ≤3.0%, and dispersibility is tested by pouring a 20 g sample into 1,000 mL of water at 25 °C with stirring at 200 rpm; a fully wetted dispersion time of <60 s is the release criterion. Microbial quality is verified by USP <61>/<62>, loss on drying by USP <731>, and elemental impurities by USP <232>/<233>.

Process failure data from production-scale fluid-bed units show that spray rates above 250 g/min produce localized overwetting, bed defluidization, and fused lumps larger than 2.0 mm that fail the <60 s dispersion criterion. Powder formulated by this route is not a true solution upon reconstitution; the dibasic calcium phosphate remains suspended, and the label must state “shake before use” rather than “solution.” Terminal product types include water-dispersible oral powders for poultry and swine, in-feed oral powders, and reconstitutable oral suspensions packaged in single-dose sachets. If the powder is intended for milk replacer, the phosphate content is calculated to account for the calcium and phosphorus already present in the milk base to avoid mineral oversupply.